Remove 2021 Remove Pharmaceutical research Remove Safety
article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

7 It is currently being evaluated in a Phase Ib/IIa clinical study, demonstrating to date a good safety profile. While favourable safety has been reported up to the Phase II, the relevance of targeting the C-terminal portion of Abeta still needs to be confirmed.

article thumbnail

Pharmaceutical Patents: A Challenge for Malaysia

Contrarian Sales Techniques

The paper was presented at the International Conference on Pharmaceutical Research and Development (IPRDC) in Kuala Lumpur, Malaysia, in June 2017. According to Zion Market Research, the global generic market is growing at more than 10 percent per year and is expected to reach approximately $380 billion by 2021.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

2022 in review: Regulation starts to catch up with AI in pharma

Pharmaceutical Technology

This could spell high-stake consequences for consumers whose privacy and safety could be at risk if AI models are not regulated. As of June 2021 , companies such as Bristol Myers Squibb , Bayer and Pfizer led the AI deals space for the pharmaceutical sectors. Major AI deals in 2022. FDA and EMA action.

Pharma 140
article thumbnail

Primate models in pharma: What the future holds

Pharmaceutical Technology

Pharmaceutical research has long relied on non-human primate models for early-stage discoveries, but their use continues to cause controversy. Globally, non-human primates make up a relatively small percentage of the animals used in research. In 2021, they accounted for 0.2% of animal testing in the UK and around 0.5%

Pharma 98
article thumbnail

Dawn of a new indication: how to study drugs for aging 

Pharmaceutical Technology

Based on preclinical research for their impact on aging, well-known drugs like metformin and rapamycin are already being considered for off-label usage, due to their accepted safety profile and cost-effectiveness. We need to act decisively now and start to do the research really diligently.”

FDA 145